Impaired tumorigenicity and decreased liver metastasis of murine neuroblastoma cells engineered to secrete interleukin-2 or granulocyte macrophage colony-stimulating factor

Cancer Gene Therapy

Volumn 5, Issue 2, 1998, Pages 67-73

  Yoshida, Hideo ^a   Enomoto, Hideki ^a   Tagawa, Masatoshi ^b   Takenaga, Keizo ^b   Tasaki, Kentaro ^a,b   Nakagawara, Akira ^b   Ohnuma, Naomi ^a   Takahashi, Hideyo ^a   Sakiyama, Shigeru ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Granulocyte macrophage colony stimulating factor; Interleukin 2; Liver metastasis; Neuroblastoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL; ARTICLE; CELL ADHESION; EXTRACELLULAR MATRIX; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; LIVER TUMOR; METASTASIS; MOUSE; NEUROBLASTOMA; PATHOLOGY; RETROVIRUS; SECRETION;

ANIMALS; CELL ADHESION; EXTRACELLULAR MATRIX; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NEUROBLASTOMA; RETROVIRIDAE; TRANSDUCTION, GENETIC;

EID: 0032018490     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol. 1991;9:581-591.
2. Carlsen NLT. How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer. 1990;61:441-446.
3. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313: 1485-1492.
4. West WH, Tauer KW, Yannelli JR, et al. Constantinfusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898-905.
5. Nsar S, McKolanis J, Pais R, et al. A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. Cancer. 1989;64:783-78 8.
6. Negrier S, Michon J, Floret D, et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with ad-vanced metastatic neuroblastoma. J. Clin Oncol. 1991;9: 1363-1370.
7. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60: 397-403.
8. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
9. Gastl G, Finstad CL, Guarini A, et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 1992;52:6229-6236.
10. + lymphocytes during virus infection in vivo. J Immunol. 1989;142:1287-1292.
11. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-379.
12. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57: 503-512.
13. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
14. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
15. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151:622-628.
16. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques. 1989;7:980-990.
17. Yamada G, Kitamura Y, Sonoda H, et al. Retrovial expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J. 1987;6:2705-2709.
18. Lee F, Yokota T, Otuka T, et al. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci USA. 1986; 83:2061-2065.
19. Miyatake S, Otsuka T, Yokota T, Lee F, Arai K-I. Structure of the chromosomal gene for granulocyte-macrophage colony stimulating factor: comparison of the mouse and human genes. EMBO J. 1985;4:2561-2568.
20. Taya Y, Mizusawa S, Nishimura S. Nucleotide sequence of the coding region of the mouse N-myc gene. EMBO J. 1986;5:1215-1219.
21. Tokunaga K, Nakamura Y, Sakata K, et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 1987;47: 5616-5619.
22. Daly JM, Reynolds HM, Rowlands BJ, Dudrich SJ, Copeland EM. Tumor growth in experimental animals. Ann Surg. 1980;191:316-322.
23. Iwakawa M, Ando K, Ohkawa H, Koike S, Chen Y-J. A murine model for bone marrow metastasis established by an i.v. injection of C-1300 neuroblastoma in A/J mice. Clin Exp Metastasis. 1994;12:231-237.
24. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985;313: 404-406.
25. Amatruda TT, Sidell N, Ranyard J, Koeffler HP. Retinoic acid treatment of human neuroblastoma cells is associated with decreased N-myc expression. Biochem Biophys Res Commun. 1985;126:1189-1195.
26. Porgador A, Gansbacher B, Bannerji R, et al. Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer. 1993;53:471-477.
27. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res. 1995;55:4941-4949.
28. Pippin BA, Rosenstein M, Jacob WF, Chiang Y, Lotze MT. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2. Cancer Gene Ther. 1994;1:35-42.
29. Ohira T, Ohe Y, Heike Y, et al. In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. J Cancer Res Clin Oncol. 1994;120:631-635.
30. Wei MX, Tamiya T, Hurford Jr RK, Boviatsis EJ, Tepper RI, Chiocca EA. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther. 1995;6:437-443.
31. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
32. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
33. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JT. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood. 1994; 83:1323-1328.
34. Sabzevari H, Gillies SD, Muller BM, Pancook JD, Reisefeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA. 1994;91:9626-9630.
35. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
36. Katsanis E, Orchard PL, Bausero MA, Gorden KB, Mcivor RS, Blazar BR. Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J. Immunother. 1994;15:81-90.
37. Brenner MK. Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapse/refractory neuroblastoma. Hum Gene Ther. 1992;3:665-676.